WEKO3
アイテム
{"_buckets": {"deposit": "ebcb3d94-857a-49f8-bca5-79cbff7eab63"}, "_deposit": {"created_by": 2, "id": "1679", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "1679"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00001679", "sets": ["30"]}, "author_link": ["8136", "8123", "8135", "8127", "8133", "8125", "8130", "8131", "8132", "8129", "8126", "8124", "8121", "8134", "8128", "8122"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-02-04", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "164", "bibliographicPageStart": "156", "bibliographicVolumeNumber": "10", "bibliographic_titles": [{"bibliographic_title": "Biomedical Reports"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The present study evaluated the changes in lipid profile, and the associations between serum protein convertase subtilisin/kexin 9 (PCSK9),microRNA (miR)122 and low?density lipoprotein variation following treatment of hepatitis C virus (HCV) genotype 1b infection with Daclatasvir/Asunaprevir. A total of 39 patients with HCV genotype 1b infection with chronic hepatitis received a 24?week treatment regimen of Daclatasvir/Asunaprevir. Laboratory data were obtained for each subject every 4 weeks during treatment and every 12 weeks after treatment.Serum miR122 and PCSK9 were measured at the start of treatment (week 0), end of treatment (week 24), 4 weeks after the end of treatment (week 28),12 weeks after the end of treatment (week 36) and 28 weeks after the end of treatment (week 52). LDL was increased at week 4 after the start \nof treatment to week 52. The increased LDL/HDL ratio at week 52 compared with week 4 was also associated with relative miR122 at week 52 At week 4,PCSK9?active form (A) was lower than that at other time points, and PCSK9?inactive form (I) exhibited the greatest increase. At week 52,PCSK9?A was higher than that during treatment, but PCSK9?I level at week 52 did not markedly differ from that any time point except for week 4. Relative miR122 at week 4 was associated with increased PCSK9?A at weeks 36 and 52 from the start of DAA. In summary, treatment of HCV with Daclatasvir/Asunaprevir resulted in elevated LDL, and relative miR122 and PCSK9?A levels in serum appeared to have some association with LDL increase.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Biomedical Reports, 10(3), pp.156-164; 2019", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Spandidos Publications"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3892/br.2019.1189", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2019, Spandidos Publications."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "20499434", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "20499442", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ichikawa, Tatsuki"}], "nameIdentifiers": [{"nameIdentifier": "8121", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyaaki, Hisamitsu"}], "nameIdentifiers": [{"nameIdentifier": "8122", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miuma, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "8123", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Taura, Naota"}], "nameIdentifiers": [{"nameIdentifier": "8124", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Motoyoshi, Yasuhide"}], "nameIdentifiers": [{"nameIdentifier": "8125", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Akahoshi, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "8126", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Junpei"}], "nameIdentifiers": [{"nameIdentifier": "8127", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takahashi, Youichi"}], "nameIdentifiers": [{"nameIdentifier": "8128", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Honda, Tetsurou"}], "nameIdentifiers": [{"nameIdentifier": "8129", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yajima, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "8130", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Uehara, Ryouhei"}], "nameIdentifiers": [{"nameIdentifier": "8131", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hino, Naoyuki"}], "nameIdentifiers": [{"nameIdentifier": "8132", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Narita, Syouhei"}], "nameIdentifiers": [{"nameIdentifier": "8133", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka, Hisaya"}], "nameIdentifiers": [{"nameIdentifier": "8134", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sasaki, Seina"}], "nameIdentifiers": [{"nameIdentifier": "8135", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakao, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "8136", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-18"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "BioRes10_156.pdf", "filesize": [{"value": "573.0 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 573000.0, "url": {"label": "BioRes10_156.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/1679/files/BioRes10_156.pdf"}, "version_id": "cd4346f5-bc30-4a64-a77e-306588b61d9b"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Direct acting anti?virals", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Hepatitis Cvirus", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Low?density lipoprotein", "subitem_subject_scheme": "Other"}, {"subitem_subject": "MicroRNA122", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Protein convertase subtilisin/kexin 9", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Changes in serum LDL, PCSK9 and microRNA?122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Changes in serum LDL, PCSK9 and microRNA?122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/38954", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-08-04"}, "publish_date": "2019-08-04", "publish_status": "0", "recid": "1679", "relation": {}, "relation_version_is_last": true, "title": ["Changes in serum LDL, PCSK9 and microRNA?122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir"], "weko_shared_id": -1}
Changes in serum LDL, PCSK9 and microRNA?122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir
http://hdl.handle.net/10069/38954
http://hdl.handle.net/10069/38954c75b3c95-3317-4063-933d-d6527580ede0
名前 / ファイル | ライセンス | アクション |
---|---|---|
BioRes10_156.pdf (573.0 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-08-04 | |||||
タイトル | ||||||
タイトル | Changes in serum LDL, PCSK9 and microRNA?122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Direct acting anti?virals | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Hepatitis Cvirus | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Low?density lipoprotein | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | MicroRNA122 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Protein convertase subtilisin/kexin 9 | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Ichikawa, Tatsuki
× Ichikawa, Tatsuki× Miyaaki, Hisamitsu× Miuma, Satoshi× Taura, Naota× Motoyoshi, Yasuhide× Akahoshi, Hiroshi× Nakamura, Junpei× Takahashi, Youichi× Honda, Tetsurou× Yajima, Hiroyuki× Uehara, Ryouhei× Hino, Naoyuki× Narita, Syouhei× Tanaka, Hisaya× Sasaki, Seina× Nakao, Kazuhiko |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The present study evaluated the changes in lipid profile, and the associations between serum protein convertase subtilisin/kexin 9 (PCSK9),microRNA (miR)122 and low?density lipoprotein variation following treatment of hepatitis C virus (HCV) genotype 1b infection with Daclatasvir/Asunaprevir. A total of 39 patients with HCV genotype 1b infection with chronic hepatitis received a 24?week treatment regimen of Daclatasvir/Asunaprevir. Laboratory data were obtained for each subject every 4 weeks during treatment and every 12 weeks after treatment.Serum miR122 and PCSK9 were measured at the start of treatment (week 0), end of treatment (week 24), 4 weeks after the end of treatment (week 28),12 weeks after the end of treatment (week 36) and 28 weeks after the end of treatment (week 52). LDL was increased at week 4 after the start of treatment to week 52. The increased LDL/HDL ratio at week 52 compared with week 4 was also associated with relative miR122 at week 52 At week 4,PCSK9?active form (A) was lower than that at other time points, and PCSK9?inactive form (I) exhibited the greatest increase. At week 52,PCSK9?A was higher than that during treatment, but PCSK9?I level at week 52 did not markedly differ from that any time point except for week 4. Relative miR122 at week 4 was associated with increased PCSK9?A at weeks 36 and 52 from the start of DAA. In summary, treatment of HCV with Daclatasvir/Asunaprevir resulted in elevated LDL, and relative miR122 and PCSK9?A levels in serum appeared to have some association with LDL increase. |
|||||
書誌情報 |
Biomedical Reports 巻 10, 号 3, p. 156-164, 発行日 2019-02-04 |
|||||
出版者 | ||||||
出版者 | Spandidos Publications | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 20499434 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 20499442 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.3892/br.2019.1189 | |||||
権利 | ||||||
権利情報 | c 2019, Spandidos Publications. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Biomedical Reports, 10(3), pp.156-164; 2019 |